Skip to content
Screener

Alkermes ALKS Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
AbbVie logo
AbbVieABBV
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS

Segments

By geography

See full
US$499.04M
IE$82.29M

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.25B+88.0%
Enterprise value$9.31B+136%
P/E124.8×+112×
P/S+2.0×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemJune 30, 2026December 31, 2025
INTANGIBLE ASSETS, NET1,761,456815
GOODWILL594,27383,027
DEFERRED TAX ASSETS123,041125,815
OTHER ASSETS62,00049,099
TOTAL ASSETS$4,393,125$2,486,993
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses$332,469$289,565

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's deferred tax assets and other non-current assets?
Alkermes (ALKS) reported deferred tax assets and other non-current assets of $62M in Q2 2026.
How has Alkermes's deferred tax assets and other non-current assets changed year-over-year?
Alkermes's deferred tax assets and other non-current assets increased by 211.4% year-over-year, from $19.91M to $62M.
What is the long-term trend for Alkermes's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Alkermes's deferred tax assets and other non-current assets has grown at a 23.2% compound annual growth rate (CAGR), from $17.32M to $49.1M.

Ask your AI about Alkermes's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude